Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients

American Journal of Hematology

Volumn 92, Issue 6, 2017, Pages 508-514

  Hiwase, Devendra K ^a,b,c,d   Singhal, Deepak ^a,b,c   Strupp, Corinna ^e   Chhetri, Rakchha ^a   Kutyna, Monika M ^a   Wee, L Amilia ^a   Harrison, Peter B ^a   Nath, Shriram V ^f   Wickham, Nicholas ^f   Hui, Chi Hung ^f   Gray, James X ^g   Bardy, Peter ^a,b,c   Ross, David M ^a,b,c,h   Lewis, Ian D ^a,b,c   Reynolds, John ⁱ   To, L Bik ^a,b,c   Germing, Ulrich ^e  

^a Haematology Department   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f Ashford Cancer Centre   (Australia)

^g QUEEN ELIZABETH HOSPITAL   (Australia)

^h FLINDERS UNIVERSITY   (Australia)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BONE MARROW DISEASE; CONTROLLED STUDY; DEATH; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INCIDENCE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IPS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; PROPORTIONAL HAZARDS MODEL; SEX; AUSTRALIA; CAUSE OF DEATH; DISEASE MANAGEMENT; GERMANY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROMES; PROCEDURES; REGISTER; REPRODUCIBILITY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CAUSE OF DEATH; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; ERYTHROCYTE TRANSFUSION; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85015652404     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24704     Document Type: Article

References (19)

1. Brunning RD, ORazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2008:85–86.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
3. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
4. Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964.
5. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. JCO. 2007;25:3503–3510.
6. Kantarjian H, O'brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351–1361.
7. Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin N Am. 2010;24:459–468.
8. Cazzola M, Della Porta MG, Travaglino E, et al. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol. 2011;38:627–634.
9. de Swart L, Smith A, Johnston TW, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170:372–383.
10. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465.
11. BG. cmprsk: Subdistribution Analysis of Competing Risks R package version 22-7. Available at: http://CRANR-projectorg/package=cmprsk. 2014.
12. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;AC-19:716–723.
13. Akaike H. Data analysis by statistical models. No to Hattatsu. 1992;24:127–133.
14. TTaG P. Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag; 2000.
15. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13:33.
16. Zhang XLF, Klein J, Zhang M. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comp Methods Prog Biomed. 2007;88:95–101.
17. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS). Haematologica. 2011;96:1433–1440.
18. Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based prognostic scoring system (WPSS) for myelodysplastic syndromes and comparison with the revised international prognostic scoring system (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29:1502–1513.
19. Bowen DT, Fenaux P, Hellstrom-Lindberg E, et al. Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:1180. author reply 1181-1182.